Literature DB >> 291337

Childhood leukemia-lymphoma. Heterogeneity of phenotypes and prognoses.

J H Kersey, T W LeBien, R Hurwitz, M E Nesbit, K J Gajl-Peczalska, D Hammond, D R Miller, P F Coccia, S Leikin.   

Abstract

Results are reported on 724 children and adolescents with acute leukemia-lymphoma. One hundred patients had immunologic marker analysis that defined the major phenotypic groups, i.e., T-cell, B-cell (Burkitt), myeloid, and the most frequent form, non-T, non-T "common" or "undifferentiated" acute leukemia. Pre-T, pre-B, and "null" leukemias are included in the latter group. Response to therapy and survival was best in non-T, non-B acute lymphocytic leukemia, intermediate in T-cell disease, and worst in B-cell (Burkitt) disease. Additional factors resulting in decreased survival include elevated peripheral leukocyte count, presence of enlarged nodes, less depression of hemoglobin and platelets, and age greater than 7 years (all associated with 'lymphomatous" disease). Other factors resulting in decreased survival include age under 3 years and depression of serum immunoglobulins. Definition of the heterogeneity of childhood leukemia-lymphoma dictates differing forms of therapy for the various types of these diseases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 291337

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies.

Authors:  Yousif Matloub; Linda Stork; Barbara Asselin; Stephen P Hunger; Michael Borowitz; Tamekia Jones; Bruce Bostrom; Julie M Gastier-Foster; Nyla A Heerema; Andrew Carroll; Naomi Winick; William L Carroll; Bruce Camitta; Meenakshi Devidas; Paul S Gaynon
Journal:  Pediatr Blood Cancer       Date:  2015-10-20       Impact factor: 3.167

2.  Immunologic diagnosis and monitoring of human acute leukemias: a review.

Authors:  M Maheu; M A Baker; J A Falk; R N Taub
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

3.  Cytotoxicity of tamoxifen for acute lymphoblastic leukaemia in vitro.

Authors:  J Blatt; D Rotenstein; S Dienes
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.